Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy (Record no. 13036)
[ view plain ]
| 000 -CABECERA | |
|---|---|
| campo de control de longitud fija | 02475nab a2200241 4500 |
| 003 - NÚMERO DE CONTROL | |
| campo de control | CO-MdCUR |
| 005 - FECHA Y HORA DE ACTUALIZACIÓN | |
| 005 | 20190605140613.0 |
| 008 - LONGITUD FIJA | |
| campo de control de longitud fija | 170814s xxu||||| |||| 00| 0 eng d |
| 040 ## - FUENTE DE CATALOGACIÓN | |
| Centro/agencia transcriptor | Remington |
| Centro catalogador/agencia de origen | CO-MdCUR |
| Normas de descripción | rda |
| 082 ## - CLASIFICACIÓN DECIMAL DEWEY | |
| edición | 21 |
| 773 0# - ENLACE AL DOCUMENTO FUENTE | |
| Número bibliográfico anfitrión | 11137 |
| Número de ítem anfitrión | 23640 |
| Encabezamiento principal | Massachusetts Medical Society |
| Lugar, editor y fecha de publicación | Boston, Massachusetts Medical Society. |
| Otro identificador del documento | 20312 |
| Título | The New England journal of medicine. |
| Número de control del registro | 11137412 |
| Número Internacional Normalizado para Publicaciones Seriadas | 0028-4793 |
| 100 1# - AUTOR PERSONAL | |
| 9 (RLIN) | 39635 |
| nombre | Cortese, Irene |
| 245 ## - TÍTULO PROPIAMENTE DICHO | |
| título | Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy |
| 264 ## - PIE DE IMPRENTA | |
| lugar (ciudad) | Boston: |
| editorial | Massachusetts Medical Society, |
| fecha | 2019. |
| 300 ## - DESCRIPCIÓN FÍSICA | |
| Extensión | 1597 - 1606 |
| 520 3# - RESUMEN | |
| Resumen | BACKGROUND<br/>Progressive multifocal leukoencephalopathy (PML) is an opportunistic brain infection that is caused by the JC virus and is typically fatal unless immune function can be restored. Programmed cell death protein 1 (PD-1) is a negative regulator of the immune response that may contribute to impaired viral clearance. Whether PD-1 blockade with pembrolizumab could reinvigorate anti–JC virus immune activity in patients with PML was unknown.<br/><br/>METHODS<br/>We administered pembrolizumab at a dose of 2 mg per kilogram of body weight every 4 to 6 weeks to eight adults with PML, each with a different underlying predisposing condition. Each patient received at least one dose but no more than three doses.<br/><br/>RESULTS<br/>Pembrolizumab induced down-regulation of PD-1 expression on lymphocytes in peripheral blood and in cerebrospinal fluid (CSF) in all eight patients. Five patients had clinical improvement or stabilization of PML accompanied by a reduction in the JC viral load in the CSF and an increase in in vitro CD4+ and CD8+ anti–JC virus activity. In the other three patients, no meaningful change was observed in the viral load or in the magnitude of antiviral cellular immune response, and there was no clinical improvement.<br/><br/>CONCLUSIONS<br/>Our findings are consistent with the hypothesis that in some patients with PML, pembrolizumab reduces JC viral load and increases CD4+ and CD8+ activity against the JC virus; clinical improvement or stabilization occurred in five of the eight patients who received pembrolizumab. Further study of immune checkpoint inhibitors in the treatment of PML is warranted. (Funded by the National Institutes of Health.) |
| 700 1# - COAUTOR PERSONAL | |
| 9 (RLIN) | 39636 |
| Nombre de persona | Muranski, Pawel |
| 700 1# - COAUTOR PERSONAL | |
| 9 (RLIN) | 39637 |
| Nombre de persona | Enose-Akahata, Yoshimi |
| 942 ## - PUNTO DE ACCESO ADICIONAL KOHA | |
| Fuente del sistema de clasificación o colocación | Dewey Decimal Classification |
| Tipo de ítem Koha | Libros |
No items available.